U.S. Molecular Cytogenetics Market Size & Outlook
U.S. molecular cytogenetics market, 2018-2028 (US$M)
Related Markets
U.S. molecular cytogenetics market highlights
- The U.S. molecular cytogenetics market generated a revenue of USD 649.0 million in 2020 and is expected to reach USD 1,543.3 million by 2028.
- The U.S. market is expected to grow at a CAGR of 11.4% from 2021 to 2028.
- In terms of segment, oncology was the largest revenue generating application in 2020.
- Personalized Medicine is the most lucrative application segment registering the fastest growth during the forecast period.
Molecular cytogenetics market data book summary
| Market revenue in 2020 | USD 649.0 million |
| Market revenue in 2028 | USD 1,543.3 million |
| Growth rate | 11.4% (CAGR from 2020 to 2028) |
| Largest segment | Oncology |
| Fastest growing segment | Personalized Medicine |
| Historical data | 2018 - 2019 |
| Base year | 2020 |
| Forecast period | 2021 - 2028 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Genetic Disorders, Oncology, Personalized Medicine, Other Applications |
| Key market players worldwide | Danaher Corp, Abbott Laboratories, Bio-Rad Laboratories Inc, Illumina Inc, Sysmex Corp, Roche Holding AG, BioView, MetaSystems, Agilent Technologies Inc, Revvity Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 39.3% of the global molecular cytogenetics market in 2020.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2028.
- In North America, U.S. molecular cytogenetics market is projected to lead the regional market in terms of revenue in 2028.
- Canada is the fastest growing regional market in North America and is projected to reach USD 332.0 million by 2028.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Molecular Cytogenetics Market Scope
Molecular Cytogenetics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. molecular cytogenetics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to molecular cytogenetics market will help companies and investors design strategic landscapes.
Oncology was the largest segment with a revenue share of 40.09% in 2020. Horizon Databook has segmented the U.S. molecular cytogenetics market based on genetic disorders, oncology, personalized medicine, other applications covering the revenue growth of each sub-segment from 2018 to 2028.
The U.S. is a key country in the context of molecular cytogenetics owing to rapid introduction of advanced technologies that improved abnormality detection at genomic level and, in turn, is helping researchers delve into deeper insights.
Stringent regulations by the FDA ensure constant developments in these technologies without compromising on safety. For instance, some of the cytogenetics laboratories are signed up with independent accreditation bodies or state controlled testing agencies for proficiency testing.
Research institutes like the Council of Regional Genetics Networks (CORN) and The College of American Pathologist (CAP) offer voluntary proficiency accreditation procedure. In the state of New York, state-run Department of Health regulates laboratory testing and certification procedures; similarly, in Oregon, state-run regulatory body accredits cytogenetics laboratories.
Reasons to subscribe to U.S. molecular cytogenetics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. molecular cytogenetics market databook
-
Our clientele includes a mix of molecular cytogenetics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. molecular cytogenetics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. molecular cytogenetics market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. molecular cytogenetics market size, by application, 2018-2028 (US$M)
U.S. Molecular Cytogenetics Market Outlook Share, 2020 & 2028 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
